NCT05673603

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

A Phase 1, Open-Label, Single Dose Parallel-Group Study of Brensocatib Following a Single Oral Administration in Subjects With or Without Renal Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Insmed Incorporated · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of the study is to determine the pharmacokinetics (PK) following a single oral dose administration of brensocatib, safety, and tolerability of brensocatib when administered to participants with impaired renal function and in healthy participants.

Conditions

• Renal Impairment

Interventions

Type	Name	Description
DRUG	Brensocatib	Oral tablet

Timeline

• Start date: 2021-07-20
• Primary completion: 2023-02-14
• Completion: 2023-02-14
• First posted: 2023-01-06
• Last updated: 2023-04-18

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study